Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis

This study has been terminated.
Sponsor:
Collaborator:
Addis Ababa University
Information provided by:
Drugs for Neglected Diseases
ClinicalTrials.gov Identifier:
NCT00832208
First received: January 29, 2009
Last updated: March 9, 2011
Last verified: March 2011